Modifying the Disease Course
At the present time, there are no medications approved by the U.S. Food and Drug Administration (FDA) for the treatment of primary-progressive MS (PPMS). Because all of the approved disease-modifying therapies work primarily by reducing inflammation in the central nervous system (CNS), they do not work as well in a disease course that is characterized by nerve degeneration rather than inflammation.
Several of the agents, including Copaxone® and an experimental drug called Rituxan, have been studied in PPMS, but unfortunately without a positive effect on progression. There are several clinical trials either recently completed or ongoing for progressive forms of MS and some are for PPMS. Read more about clinical trials in MS.
Even without an approved disease-modifying therapy, however, there is a lot that people with PPMS and their healthcare teams can do to manage the disease.